What is the half-life of TB-500?

TB-500 has an approximate elimination half-life of 3 h. Short-acting — protocols usually dose daily.

How long does TB-500 stay in your system?

Roughly 97% of a dose has cleared after five half-lives — about ~15 h for TB-500. That is the window that matters for washouts, bloodwork and surgery.

TB-500 is typically administered by the subcutaneous route. Research range: 2 mg subcutaneous twice weekly, or 5 mg weekly, for 4–6 weeks.

What are the risks of TB-500?

Long-term human safety unknown Theoretical concern around abnormal cell growth pathways — avoid with cancer history Not FDA-approved FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

TB-500

tb500 t-beta

Thymosin Beta-4 fragment — soft-tissue and tendon recovery. Long half-life relative to fragment size.

Half-life: 3 h
Out of system: ~15 h
Route: Subcutaneous
Level: Beginner

Short-acting — protocols usually dose daily. After the last dose, roughly 97% has cleared in ~15 h (five half-lives) — the window that matters for washouts, bloodwork and surgery.

What TB-500 is used for

Soft-tissue and muscle recovery (thymosin beta-4 fragment)
Tendon and ligament repair in animal models
Pairs with BPC-157 in the most-discussed recovery stack

How it's typically used

Research range: 2 mg subcutaneous twice weekly, or 5 mg weekly, for 4–6 weeks.

What to watch for

Long-term human safety unknown
Theoretical concern around abnormal cell growth pathways — avoid with cancer history
Not FDA-approved
FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

Common questions

What is the half-life of TB-500?: TB-500 has an approximate elimination half-life of 3 h. Short-acting — protocols usually dose daily.
How long does TB-500 stay in your system?: Roughly 97% of a dose has cleared after five half-lives — about ~15 h for TB-500. That is the window that matters for washouts, bloodwork and surgery.
How is TB-500 taken?: TB-500 is typically administered by the subcutaneous route. Research range: 2 mg subcutaneous twice weekly, or 5 mg weekly, for 4–6 weeks.
What are the risks of TB-500?: Long-term human safety unknown Theoretical concern around abnormal cell growth pathways — avoid with cancer history Not FDA-approved FDA compounding status in flux: BPC-157 removed from the 503A Category 2 list (Apr 2026); PCAC review of BPC-157, TB-500, KPV and MOTS-C set for Jul 23-24, 2026.

About Healing & recovery

What they are: Repair peptides — short amino-acid chains studied for soft-tissue, tendon, and gut-lining healing. Almost all the evidence is animal or preclinical; human trials are scarce.
How they're run: Reconstituted from a lyophilised (freeze-dried) powder and injected subcutaneously, usually daily, in blocks of 4–6 weeks around a specific injury.
What to watch: None are approved drugs, so purity depends entirely on the source. Effects are gradual — judge a block by whether the injury measurably improved, not by how you feel on day 3.

Full guide

TB-500 Alone: Tracking the Thymosin Beta-4 Fragment for Recovery

A focused tracking guide for TB-500 used by itself, separating its slower recovery signal from BPC-157 and confounders.

Other healing & recovery

Peptid AI is an educational and self-tracking tool — not a medical service, and not a vendor. Nothing here is medical advice, a prescription, or an endorsement. Doses reflect what is commonly reported in research literature; they are not recommendations. Many compounds listed are experimental, not approved for human use, and/or controlled substances that are illegal to possess without a prescription in many countries. Always consult a qualified physician before starting, changing, or stopping any protocol.